MicroRNA在去势抵抗性前列腺癌中的研究进展

Advances in MicroRNA in castration-resistant prostate cancer

前列腺癌(prostate cancer,PCa)是男性生殖系最常见的恶性肿瘤之一,主要通过雄激素剥夺治疗(androgen deprivation therapy,ADT),然而大多数患者ADT后最终会进展为去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)。近年来,微小RNA(microRNA,miRNA)被发现与CRPC的发生和发展密切相关,其对代谢重塑、表观遗传学修饰、雄激素受体(androgen receptor,AR)和一些非AR相关通路都有着直接或间接的影响。此外,miRNA的异常表达可成为CRPC肿瘤预测预后及疗效评价的强力标志物,并且在逆转CRPC患者耐药中展示出巨大的潜力。本文将对miRNA与CRPC有关研究的最新进展作一综述。

Prostate cancer(PCa)is one of the most common malignant tumor in the male reproductive system,which is primarily treated with androgen deprivation therapy(ADT).However,most patients with PCa will eventually develop castration-resistant prostate cancer(CRPC)after ADT therapy.In recent years,microRNA(miRNA)have been found to be closely related to the occurrence and progression of CRPC and have direct or indirect effects on its metabolic reprogramming,epigenetics modification,androgen receptor(AR),and some non-AR-related pathways.In addition,their abnormal expression can serve as powerful biomarkers for predicting patient prognosis and drug efficacy,particularly showing great potential in reversing drug resistance for CRPC patients.This article aims to review the latest research progress on miRNA in relation to CRPC.